23 results on '"Wang, Zhi ‐ Qiang"'
Search Results
2. Association between cigarette smoking and colorectal cancer sidedness: A multi-center big-data platform-based analysis
- Author
-
Yang, Lu-Ping, Wang, Zi-Xian, Zhang, Rui, Zhou, Na, Wang, A-Man, Liang, Wei, Wang, Zhi-Qiang, Luo, Hui-Yan, Wang, Feng, Liu, Ji-Wei, Liu, Fang, Zhang, Xiao-Chun, Liu, Yun-Peng, and Jin, Ying
- Published
- 2021
- Full Text
- View/download PDF
3. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis
- Author
-
Wang Zhi-Qiang, Mei Qi, Li Ji-Bin, You Rui, Liu You-Ping, Sun Rui, Hu Guang-Yuan, Chen Ming-Yuan, and Hua Yi-Jun
- Subjects
Nasopharyngeal carcinoma ,IMRT ,Chemotherapy ,Nimotuzumab ,Prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background To assess the efficacy of Nimotuzumab in combination with first-line chemoradiotherapy treatment in Chinese patients with primary III-IVb stage nasopharyngeal carcinoma. Methods Patients with primary locoregionally advanced nasopharyngeal carcinoma who were treated with intensity-modulated radiotherapy (IMRT) and concurrent cisplatin-based chemotherapy between January 2008 and December 2013 at a single institution were retrospectively reviewed. Group A received at least 6 doses of Nimotuzumab, while Group B did not receive Nimotuzumab. A propensity score matching method was used to match patients from each group in a 1:3 ratio. Results In total, 730 eligible patients were propensity matched, with 184 patients in Group A and 546 patients in Group B. Significant differences were not observed in the patient and tumor characteristics between Group A and Group B. At a median follow-up of 74.78 months (range 3.53–117.83 months), locoregional recurrence, distant failure and death were observed in 10.68, 11.10 and 16.03% of all patients, respectively. The estimated 5-year locoregional relapse–free survival, distant metastasis–free survival, progression-free survival and overall survival in the Group A versus Group B were 85.34% versus 89.79% (P = 0.156), 93.09% versus 85.61% (P = 0.012), 79.96% versus 77.99% (P = 0.117) and 88.91% versus 78.30% (P = 0.006), respectively. Conclusions This nimotuzumab-containing regimen resulted in improved long-term survival of III-IVb stage NPC patients and warrants further prospective evaluation.
- Published
- 2019
- Full Text
- View/download PDF
4. The Immunoscore system predicts prognosis after liver metastasectomy in colorectal cancer liver metastases
- Author
-
Wang, Yun, Lin, Hao-cheng, Huang, Ma-yan, Shao, Qiong, Wang, Zhi-qiang, Wang, Feng-hua, Yuan, Yun-fei, Li, Bin-kui, Wang, De-shen, Ding, Pei-rong, Chen, Gong, Wu, Xiao-jun, Lu, Zhen-hai, Li, Li-ren, Pan, Zhi-zhong, Sun, Peng, Yan, Shu-mei, Wan, De-sen, Xu, Rui-hua, and Li, Yu-hong
- Published
- 2017
- Full Text
- View/download PDF
5. The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysis
- Author
-
Li Ji-Bin, You Rui, Chen Ming-Yuan, Hua Yijun, Mei Qi, Wang Zhi-Qiang, Hu Guang-Yuan, Sun Rui, and Liu You-Ping
- Subjects
0301 basic medicine ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Antibodies, Monoclonal, Humanized ,Gastroenterology ,lcsh:RC254-282 ,Group B ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Genetics ,Nasopharyngeal carcinoma ,Medicine ,Nimotuzumab ,Humans ,Chemotherapy ,Stage (cooking) ,Neoplasm Metastasis ,IMRT ,Propensity Score ,Neoplasm Staging ,Retrospective Studies ,business.industry ,Nasopharyngeal Neoplasms ,Middle Aged ,medicine.disease ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Radiation therapy ,Regimen ,030104 developmental biology ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Propensity score matching ,Female ,business ,Chemoradiotherapy ,medicine.drug ,Research Article - Abstract
BackgroundTo assess the efficacy of Nimotuzumab in combination with first-line chemoradiotherapy treatment in Chinese patients with primary III-IVb stage nasopharyngeal carcinoma.MethodsPatients with primary locoregionally advanced nasopharyngeal carcinoma who were treated with intensity-modulated radiotherapy (IMRT) and concurrent cisplatin-based chemotherapy between January 2008 and December 2013 at a single institution were retrospectively reviewed. Group A received at least 6 doses of Nimotuzumab, while Group B did not receive Nimotuzumab. A propensity score matching method was used to match patients from each group in a 1:3 ratio.ResultsIn total, 730 eligible patients were propensity matched, with 184 patients in Group A and 546 patients in Group B. Significant differences were not observed in the patient and tumor characteristics between Group A and Group B. At a median follow-up of 74.78 months (range 3.53–117.83 months), locoregional recurrence, distant failure and death were observed in 10.68, 11.10 and 16.03% of all patients, respectively. The estimated 5-year locoregional relapse–free survival, distant metastasis–free survival, progression-free survival and overall survival in the Group A versus Group B were 85.34% versus 89.79% (P = 0.156), 93.09% versus 85.61% (P = 0.012), 79.96% versus 77.99% (P = 0.117) and 88.91% versus 78.30% (P = 0.006), respectively.ConclusionsThis nimotuzumab-containing regimen resulted in improved long-term survival of III-IVb stage NPC patients and warrants further prospective evaluation.
- Published
- 2019
6. A Population-Based Study on the Prognostic factors and Efficacy of Adjuvant Chemotherapy in the Postoperative Stage for Patients with Stage IIA Non-Small Cell Lung Cancer.
- Author
-
Wang, Wei, Teng, Fei, Bu, Shi, Xu, Wei, Cai, Qing-Chun, Jiang, Yue-Quan, and Wang, Zhi-Qiang
- Subjects
NON-small-cell lung carcinoma ,PROGNOSIS ,ADJUVANT chemotherapy ,PROPORTIONAL hazards models ,CANCER hospitals ,LOBECTOMY (Lung surgery) - Abstract
aimed to design a nomogram survival prediction by means of the figures retrieved from the Surveillance, Epidemiology, and End Results (SEER) source bank, and to predict the overall survival (OS) of patients with stage IIA non-small cell lung cancer (NSCLC) after surgery. Methods: Data for 4511 patients who had been diagnosed with postoperative stage IIA NSCLC were collected from the SEER databank, while information on 528 patients was acquired from the Chongqing University Cancer Hospital for the external validation cohort. The independent risk factors that affected the prognosis were identified using a multivariate Cox proportional hazards regression model (also used to conduct a nomogram). A survival analysis between the low- and the high-risk groups was performed using the Kaplan–Meier method. Furthermore, a subgroup analysis was conducted of the two groups using the Kaplan–Meier method to determine whether the patients had received adjuvant chemotherapy. Results: The following five variables were integrated into the nomogram: sex (female: HR 1.73, 95% CI 0.64– 0.83), age (≥ 60: HR 1.61, 95% CI 1.39– 1.87), differentiation grade (grade II: HR 2.19, 95% CI 1.66– 2.88; grade III: HR 2.65, 95% CI 2.00– 3.51; grade IV: HR 3.17, 95% CI 1.99– 5.03), surgery (lobectomy: HR 0.72, 95% CI 0.59– 0.86), and lymph node resection (> 12: HR 0.82, 95% CI 0.70– 0.96). Furthermore, the patients selected were categorized into high- and low-risk groups. The OS rate was significantly lower in the high-risk group than in the low-risk group (P < 0.001). Finally, adjuvant chemotherapy was highly correlated with OS in the high-risk set (P = 0.035); however, adjuvant chemotherapy was not related to OS in the low-risk set. Conclusion: A nomogram was created as a reliable, convenient scheme that could predict OS, and it was determined that the high-risk feature patients identified by the nomogram gained benefits from adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Prognostic factors for survival of stage IB upper lobe non-small cell lung cancer patients: A retrospective study in Shanghai, China
- Author
-
Wang, Wen-li, Shen-tu, Yang, and Wang, Zhi-qiang
- Published
- 2011
- Full Text
- View/download PDF
8. Identification and Validation of Immune-Related Gene for Predicting Prognosis and Therapeutic Response in Ovarian Cancer.
- Author
-
Zhang, Zhao-Cong, Guo, Jun-Nan, Zhang, Ning, Wang, Zhi-Qiang, Lou, Ge, Cui, Bin-Bin, and Yang, Chang
- Subjects
OVARIAN cancer ,PROGNOSIS ,REGULATORY T cells ,OVERALL survival ,IMMUNE checkpoint inhibitors ,PROGNOSTIC models - Abstract
Ovarian cancer (OC) is a devastating malignancy with a poor prognosis. The complex tumor immune microenvironment results in only a small number of patients benefiting from immunotherapy. To explore the different factors that lead to immune invasion and determine prognosis and response to immune checkpoint inhibitors (ICIs), we established a prognostic risk scoring model (PRSM) with differential expression of immune-related genes (IRGs) to identify key prognostic IRGs. Patients were divided into high-risk and low-risk groups according to their immune and stromal scores. We used a bioinformatics method to identify four key IRGs that had differences in expression between the two groups and affected prognosis. We evaluated the sensitivity of treatment from three aspects, namely chemotherapy, targeted inhibitors (TIs), and immunotherapy, to evaluate the value of prediction models and key prognostic IRGs in the clinical treatment of OC. Univariate and multivariate Cox regression analyses revealed that these four key IRGs were independent prognostic factors of overall survival in OC patients. In the high-risk group comprising four genes, macrophage M0 cells, macrophage M2 cells, and regulatory T cells, observed to be associated with poor overall survival in our study, were higher. The high-risk group had a high immunophenoscore, indicating a better response to ICIs. Taken together, we constructed a PRSM and identified four key prognostic IRGs for predicting survival and response to ICIs. Finally, the expression of these key genes in OC was evaluated using RT-qPCR. Thus, these genes provide a novel predictive biomarker for immunotherapy and immunomodulation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
9. Prognostic effects of 25-hydroxyvitamin D levels in gastric cancer
- Author
-
Ren Chao, Qiu Miao-zhen, Wang De-shen, Luo Hui-yan, Zhang Dong-sheng, Wang Zhi-qiang, Wang Feng-hua, Li Yu-hong, Zhou Zhi-wei, and Xu Rui-hua
- Subjects
vitamin D ,Gastric cancer ,Prognosis ,Elisa ,Medicine - Abstract
Abstract Background Results from large epidemiologic studies on the association between vitamin D and gastric cancer are controversial. Vitamin D significantly promotes apoptosis in the undifferentiated gastric cancer cell, but the prognostic effects of its levels are unknown. Methods 197 gastric carcinoma patients who received treatment in the cancer centre of Sun Yat-sen University from January 2002 to January 2006 were involved in the study. The stored blood drawn before any treatment was assayed for 25-hydroxyvitamin D levels. The clinicopathologic data were collected to examine the prognostic effects of vitamin D. Results The mean vitamin D levels of the 197 gastric patients was 49.85 ± 23.68 nmol/L, among whom 114(57.9%) were deficient in Vitamin D(< 50 nmol/L), 67(34%) were insufficient (50-75 nmol/L) and 16(8.1%) were sufficient (> 75 nmol/L). Clinical stage (P = 0.004) and lymph node metastasis classification (P = 0.009) were inversely associated with vitamin D levels. The patients with high vitamin D levels group (≥ 50 nmol/L) had a higher overall survival compared with the low vitamin D levels group (< 50 nmol/L)(P = 0.018). Multivariate analysis indicated that vitamin D levels were an independent prognostic factor of gastric cancer (P = 0.019). Conclusions Vitamin D deficiency may be associated with poor prognosis in gastric cancer.
- Published
- 2012
- Full Text
- View/download PDF
10. Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy.
- Author
-
Liang, Jie-ying, Xi, Shao-yan, Shao, Qiong, Yuan, Yun-fei, Li, Bin-kui, Zheng, Yun, Wang, De-shen, Wu, Xiao-jun, Ding, Pei-rong, Chen, Gong, Li, Li-ren, Wang, Feng-hua, Wang, Zhi-qiang, Pan, Zhi-zhong, Xu, Rui-hua, and Li, Yu-hong
- Subjects
LIVER cancer ,LIVER metastasis ,COLORECTAL cancer ,METASTASIS ,PROGNOSIS ,PORTAL vein surgery ,LIVER surgery - Abstract
Various scoring systems have been proposed to predict the postoperative prognosis of colorectal liver metastasis (CRLM), including the clinical risk score (CRS), the immunoscore and so on. Recently, histopathological growth patterns (HGPs) have been recognized. However, the correlation between HGPs and the immunoscore, and their prognostic values in patients with CRLM after liver resection remain undetermined. In this study, HGPs were retrospectively evaluated in H&E-stained slides from 166 CRLM patients. The immunoscore was calculated according to the densities of immunostained CD3 + and CD8 + cells. A risk score combining HGPs, the immunoscore and the CRS was defined and divided patients into the low-, medium- and high-risk group. Our results showed that the densities of CD3 + and CD8 + cells were higher in the desmoplastic HGP (dHGP) group than in the non-dHGP group, and the proportion of high immunoscores was also higher in the dHGP group (51.9% vs. 33.0%, respectively, P = 0.020). Patients with the dHGP had significantly longer relapse-free survival (RFS) and overall survival (OS) than those with the non-HGP. The low-risk group showed significantly higher 2-year RFS and 5-year OS rates than the other two groups (RFS: 76.2%, 43.7% and 33.1%, respectively; P < 0.001; OS: 89.7%, 54.4% and 33.3%, respectively; P < 0.001). In conclusion, the dHGP correlates with relatively high immunoscores, predicting a favorable prognosis independent of the immunoscore and CRS. A novel risk score combining HGPs, the immunoscore and the CRS may be used for the stratification of CRLM patients' survival. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Clinicopathologic Features and Prognosis of BRAF Mutated Colorectal Cancer Patients.
- Author
-
Guan, Wen-Long, Qiu, Miao-Zhen, He, Cai-Yun, Yang, Li-Qiong, Jin, Ying, Wang, Zhi-Qiang, Li, Yu-Hong, Xu, Rui-Hua, and Wang, Feng-Hua
- Subjects
COLORECTAL cancer ,CANCER patients ,PROGNOSIS ,CANCER prognosis ,FAMILY history (Medicine) ,HEREDITARY nonpolyposis colorectal cancer - Abstract
Background: BRAF
V600E mutation is associated with poor prognosis of colorectal cancer (CRC) patients, but the comparison of clinic-pathologic features between V600E and non-V600E mutation was not well-known in CRC patients. The aim of this study is to evaluate the clinical and pathological features, prognostic value of BRAF mutations in CRC. Methods: We conducted a retrospective study to characterize the clinical and pathological features and survival of patients with BRAF mutated CRC. Patients were classified according to BRAF status as BRAFV600E mutation and non-V600E mutations. Difference of characteristics and survival between the two groups was analyzed. Results: There was no significant difference in gender, family history, location of primary tumor, metastatic sites between patients with BRAF -V600E mutation and non-V600E mutations. Patients with V600E mutation were younger than those with non-V600E mutations (p = 0.002). Patients with BRAFV600E mutation showed a poorer outcome than those with non-V600E mutations (23.1 vs. 49.9 months, respectively, p = 0.0024). Lack of CDX2 expression was associated with worse prognosis (mOS: 9.4 m vs. not reached, respectively, p = 0.016). Status of V600E mutation did not affect the mPFS and ORR of first-line or second-line treatment. Conclusion: BRAFV600E mutation defines a distinct subgroup of CRC with worse prognosis. Lack of CDX2 expression is associated with poor OS. Status of V600E mutation did not affect the mPFS of first-line or second-line treatment. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
12. Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis.
- Author
-
He, Cai‐Yun, Qiu, Miao‐Zhen, Yang, Xin‐Hua, Zhou, Da‐Lei, Ma, Jiang‐Jun, Long, Ya‐Kang, Ye, Zu‐Lu, Xu, Bo‐Heng, Zhao, Qi, Jin, Ying, Lu, Shi‐Xun, Wang, Zhi‐Qiang, Guan, Wen‐Long, Zhao, Bai‐Wei, Zhou, Zhi‐Wei, Shao, Jian‐Yong, and Xu, Rui‐Hua
- Subjects
EPSTEIN-Barr virus ,STOMACH cancer ,TUMOR classification ,NUCLEOTIDE sequencing ,CANCER patients ,EXPERIMENTAL design ,CANCER prognosis ,PROGNOSIS - Abstract
Purpose: To identify how Epstein‐Barr virus (EBV) status combined with molecular profiling predicts the prognosis of gastric cancer patients and their associated clinical actionable biomarkers. Experimental Design: A next‐generation sequencing assay targeting 295 cancer‐related genes was performed in 73 EBV‐associated gastric cancer (EBVaGC) and 75 EBV‐negative gastric cancer (EBVnGC) specimens and these results were compared with overall survival (OS). Results: PIK3CA, ARID1A, SMAD4, and PIK3R1 mutated significantly more frequently in EBVaGC compared with their corresponding mutation rate in EBVnGC. As the most frequently mutated gene in EBVnGC (62.7%), TP53 also displayed a mutation rate of 15.1% in EBVaGC. PIK3R1 was revealed as a novel mutated gene (11.0%) associated almost exclusively with EBVaGC. PIK3CA, SMAD4, PIK3R1, and BCOR were revealed to be unique driver genes in EBVaGC. ARID1A displayed a significantly large proportion of inactivated variants in EBVaGC. A notable finding was that integrating the EBV status with tumor mutation burden (TMB) and large genomic instability (LGI) categorized the tumors into four distinct molecular subtypes and optimally predicted patient prognosis. The corresponding median OSs for the EBV+/TMB‐high, EBV+/TMB‐low, EBV‐/LGI‐, and EBV‐/LGI+ subtypes were 96.2, 75.3, 44.4, and 20.2 months, respectively. The different subtypes were significantly segregated according to distinct mutational profiles and pathways. Conclusions: Novel mutations in PIK3R1 and TP53 genes, driver genes such as PIK3CA, SMAD4, PIK3R1, BCOR, and ARID1A, and distinguished genomic profiles from EBVnGC were identified in EBVaGC tumors. The classification of gastric cancer by EBV, TMB, and LGI could be a good prognostic indicator, and provides distinguishing, targetable markers for treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. 152. SINTILIMAB PLUS CISPLATIN AND PACLITAXEL INDUCTION TREATMENT FOR BORDERLINE RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A PHASE II CLINICAL TRIAL.
- Author
-
Wu, Jia-Di, Wang, Zhi-Qiang, Zhao, Ze-Rui, Li, Qiao-Qiao, Li, Zhi-Chao, and Li, Yu-Hong
- Subjects
- *
ESOPHAGEAL cancer , *SQUAMOUS cell carcinoma , *CHEMORADIOTHERAPY , *IMMUNOTHERAPY , *CISPLATIN , *PACLITAXEL , *CLINICAL trials , *PROGNOSIS - Abstract
Background An increasing number of clinical studies focus on investigating the use of immunotherapy in the treatment of esophageal cancer. This phase II trial (NEOCRTEC-2001 clinical trial) aimed to assess the safety and efficacy of sintilimab in combination with cisplatin and paclitaxel induction immunochemotherapy followed by surgery for locally advanced borderline-resectable esophageal squamous cell carcinoma (BR-ESCC). Methods Patients with primary tumor or bulky lymph nodes that might invade nearby organs were eligible. Treatment started with 2–4 cycles of induction immunochemotherapy, followed by surgery if the tumor was assessed resectable, or by radical concurrent chemoradiotherapy if unresectable. The primary endpoint was pathologically proven complete resection (R0) rate. The secondary end points included pathological complete response (pCR) rate, overall survival (OS), progression-free survival (PFS), adverse events and postoperative complication. Results From September 2020 to now, a total of 34 patients were enrolled. After immunochemotherapy, 21 patients (61.8%) received surgery and 13 (38.2%) did not. All patients underwent McKeown procedure, and median operation time was 295 minutes (range 201–489 minutes). All patients received esophageal reconstruction using gastric tube, and underwent cervical anastomosis. An average of 46.6 lymph nodes were dissected, and positive lymph nodes were observed in 5 of the 21 patients. R0 resection was confirmed in 20 patients (58.8%). One patient underwent R2 resection because of tumor invasion of the aorta. Pathologic complete response was confirmed in 6 patients (6/34, 17.6%), while 5 patients (5/34, 14.7%) had few or no regressive changes (TRG3). Conclusion The treatment strategy of induction immunochemotherapy followed by surgery is promising for patients with locally advanced borderline-resectable esophageal squamous cell carcinoma. The whole results of pathologic response and prognostic value are awaited with interest. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. The pretreatment thrombocytosis as one of prognostic factors for gastric cancer: A systematic review and meta-analysis.
- Author
-
Wang, Yong-Hong, Kang, Jin-Ke, Zhi, Yong-Fa, Zhang, Yi, Wang, Zhi-Qiang, Zhou, Qing, Niu, Wen-Yu, and Ma, Ming-Jie
- Abstract
Background& Aims: At present, increasing reports have shown that pretreatment platelet count was associated with the prognosis of many types of cancer. We performed rounded analysis to comprehensively analyze and evaluate the prognostic significance of pretreatment thrombocytosis for patients with gastric cancer.Methods: We identified relevant studies by searching database including PubMed, Embase, Cochrane Library and Web of Science. The relative risk (RR) with its 95% confidence interval (CI) was used to assess the correlation between thrombocytosis and overall survival (OS) of gastric cancer patients. We also conducted subgroup analysis and sensitivity analysis for the prognostic effect of thrombocytosis on OS. The analysis was performed and assessed using Review Manager 5.2.Results: A total of nine studies including 7158 participants were included in this systematic review. Analysis results showed that pretreatment thrombocytosis had a close relationship with 1, 3 and 5 years survival of gastric cancer, with the pooled RRs being 0.80 (95% CI 0.71-0.90; P = 0.0004), 0.65 (95% CI 0.45-0.92; P = 0.02) and 0.64 (95% CI 0.47-0.87; P = 0.004) respectively.Conclusions: The present rounded analysis suggests that pretreatment thrombocytosis may have significant association with poor survival of patients with gastric cancer. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
15. Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma.
- Author
-
Zhang, Fei, Wang, Yun, Sun, Peng, Wang, Zhi-qiang, Wang, De-shen, Zhang, Dong-sheng, Wang, Feng-hua, Fu, Jian-hua, Xu, Rui-hua, and Li, Yu-hong
- Subjects
FIBRINOGEN ,BLOOD coagulation factors ,METASTASIS ,PROGNOSIS ,MESENCHYMAL stem cells ,SQUAMOUS cell carcinoma ,EPITHELIAL cell tumors - Abstract
Purpose: Hyperfibrinogenemia is associated with unfavorable prognosis and advanced tumor behavior in various malignancies, including esophageal squamous cell carcinoma (ESCC). However, its biological function in ESCC is unknown. The present study was designed to further validate the prognostic value of preoperative plasma hyperfibrinogenemia and evaluate the biological role of fibrinogen, as well as the underlying mechanism in ESCC. Methods: Data from 452 cases with newly diagnosed ESCC followed by curative surgery between 2006 and 2010 were retrospectively evaluated. The Clauss method was utilized to measure the preoperative plasma fibrinogen level. Correlations between the fibrinogen level and clinicopathologic characteristics and survival analysis were performed. The effects of fibrinogen on malignant behaviors, including tumor cell viability, colony formation, migration, and invasion, were also investigated. Results: The optimal cut-off value for plasma fibrinogen level was defined as 4.0 g/L according to recommendations. Thus, the proportion of hyperfibrinogenemia was 24.8% (112/452). Preoperative plasma hyperfibrinogenemia was significantly associated with advanced tumor length, deep tumor invasion, advanced tumor-node-metastasis stage, alcohol consumption, a higher white blood cell count, a higher platelet count, and high globulin levels. Univariate survival analysis revealed that compared to those with normal plasma fibrinogen levels, patients with hyperfibrinogenemia tended to have poorer disease-free survival (DFS) [hazard ratio (HR), 1.692; 95% confidence interval (CI), 1.304-2.196; P < 0.001] and overall survival (OS) (HR 1.864; 95% CI 1.424-2.440; P < 0.001). In the multivariate Cox regression models, these factors remained independent predictors for impaired DFS (HR 1.491; 95% CI 1.138-1.955; P = 0.004) and OS (HR 1.648; 95% CI 1.246-2.180; P < 0.001) after adjusting for other confounding variables. In addition, fibrinogen could significantly promote cell migration and invasion but not proliferation. Moreover, it could also induce epithelial-mesenchymal transition (EMT) and increase the levels of p-PTEN, p-AKT, and p-mTOR in ESCC cell lines. Conclusions: Preoperative plasma hyperfibrinogenemia might serve as an independent predictor of unfavorable survival in ESCC. Furthermore, fibrinogen may promote cell motility by inducing EMT via the p-AKT/p-mTOR pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
- Author
-
Wang, Zhi-Qiang, Zhang, Mei-Yin, Deng, Mei-Ling, Weng, Nuo-Qing, Wang, Hui-Yun, and Wu, Shao-Xiong
- Subjects
- *
MICRORNA , *BIOMARKERS , *GLIOBLASTOMA multiforme , *MICROARRAY technology , *SERUM - Abstract
MicroRNAs (miRNAs) are short noncoding RNAs that play critical roles in human malignancies and can be used as biomarkers for cancer. Until now, a number of biomarkers for prognosis of glioblastoma (GBM) have been reported in tumor tissues but only a few biomarkers in circulating fluid. Using a custom microarray, we previously identified 19 differentially expressed miRNAs in serum of patients with GBM. In this study, we investigated whether 3 of the 19 miRNAs in serum could be used as prognostic biomarkers for patients with GBM. We first validated the serum levels of 3 candidate miRNAs in an independent cohort of 24 GBM patients and 12 healthy volunteers by real-time quantitative reverse transcription PCR (qRT-PCR), and then evaluated the prognostic value of these miRNAs in a total of 36 GBM patients. The results show that the serum levels of the 3 miRNAs (miR-451a, miR-485-3p and miR-4298) determined by qRT-PCR are significantly different between 24 GBM patients and 12 healthy volunteers (all P <0.05) and are in concordance with the results of microarray analysis. High serum level of miR-451a is correlated with positive tumor O(6)-methylguanine-DNA methyltransferase (MGMT) expression (P = 0.040). Survival analysis showed that low serum miR-485-3p level is associated with poor progression-free survival (PFS) (P < 0.004) and overall survival (OS) (P < 0.023). Furthermore, univariate and multivariate Cox analyses demonstrated that that serum miR-485-3p expression is a significant independent prognostic factor for PFS and OS in GBM patients. In conclusion, serum miR-485-3p level is reduced and might be a potential prognostic biomarker in GBM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
- Author
-
He, Ming-ming, Zhang, Dong-sheng, Wang, Feng, Wang, Zi-xian, Yuan, Shu-qiang, Wang, Zhi-qiang, Luo, Hui-yan, Ren, Chao, Qiu, Miao-zhen, Jin, Ying, Wang, De-shen, Chen, Dong-liang, Zeng, Zhao-lei, Li, Yu-hong, He, Yang-yang, Hao, Yuan-tao, Guo, Pi, Wang, Feng-hua, Zeng, Yi-xin, and Xu, Rui-hua
- Subjects
FOLINIC acid ,STOMACH cancer treatment ,STOMACH cancer patients ,CANCER chemotherapy ,PHARMACOGENOMICS ,CLINICAL trials ,THERAPEUTICS ,ANTINEOPLASTIC agents ,COMBINATION drug therapy ,COMPARATIVE studies ,FLUOROURACIL ,HETEROCYCLIC compounds ,RESEARCH methodology ,MEDICAL cooperation ,OXIDOREDUCTASES ,PROGNOSIS ,RESEARCH ,STOMACH tumors ,TRANSFERASES ,EVALUATION research - Abstract
Background: The first one-arm phase II trial aimed to evaluate and predict efficacy and safety of S-1 plus oral leucovorin (S-1/LV) as first-line chemotherapy for patients with advanced gastric cancer (AGC), using S-1 pharmacogenetic pathway approach.Patients and Methods: A total of 39 patients orally took S-1 at conventional dose and LV simultaneously at a dose of 25 mg twice daily for a week, within a 2-week cycle. The primary endpoint was overall response rate (ORR), while the secondary endpoints were progression-free survival (PFS), time to failure (TTF), overall survival (OS), disease control rate (DCR), and adverse events (AEs). Peripheral blood was sampled prospectively for baseline expression of dihydropyrimidine dehydrogenase (DPD), orotate phosphoribosyltransferase (OPRT), thymidine phosphorylase (TP), and thymidylate synthase (TS), CYP2A6 gene polymorphisms, and 5-FU pharmacokinetics.Results: The ORR and DCR were 41.0 and 76.9%. The median PFS, TTF, and OS were 4.13, 3.70, and 11.40 months. Grade 3-4 AEs occurred in only 13 patients, and grade 4 AEs occurred in only 1 of them. High OPRT/TS and peritoneal metastasis (vs. liver metastasis) independently predicted responding. High OPRT/DPD independently predicted grade 3-4 AEs. High AUC0-24h of 5-FU and metastatic/recurrent sites ≤2 (vs. >3) independently predicted prolonged PFS. Low baseline plasmic DPD independently predicted prolonged OS.Conclusions: Two-week, oral S-1/LV regimen demonstrated promising efficacy and safety as first-line chemotherapy for AGC. CLINICALTRIALS.Gov Identifier: NCT02090153. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
18. HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: A prospective cohort observation.
- Author
-
Qiu, Miao‐Zhen, Li, Qian, Wang, Zhi‐Qiang, Liu, Tian‐Shu, Liu, Qing, Wei, Xiao‐Li, Jin, Ying, Wang, De‐Shen, Ren, Chao, Bai, Long, Zhang, Dong‐Sheng, Wang, Feng‐Hua, Li, Yu‐Hong, and Xu, Rui‐Hua
- Abstract
The monoclonal antibody trastuzumab has brought survival benefit to patients with advanced gastric cancer (AGC) that have human epidermal growth factor receptor 2 (HER2) over expression or amplification. This study was designed to compare the clinical outcomes of HER2-negative and HER2-positive AGC patients with or without trastuzumab treatment. There were three groups of patients enrolled for analysis. Group A was 51 HER2-positive AGC patients treated with trastuzumab and chemotherapy; group B was a matched control group of 47 HER2-positive patients who received chemotherapy only; group C was a matched group of 251 HER2-negative patients who received chemotherapy. All the patients were enrolled at Sun Yat-sen University Cancer Center or Zhongshan Hospital, Fudan University between January 2010 and December 2012. The primary endpoint was overall survival (OS). The Kaplan-Meier method and log-rank test were used for survival analysis. The median duration of follow-up was 13.5 months (range 5-18.6 months). The median OS of these three groups of patients was 14.8 months, 11.3 months and 14.4 months respectively ( p < 0.001). The survival difference between group A and B was significant, p < 0.001. Similarly, there was significant difference between group B and C, p < 0.001. Moreover the survival between group A and C was comparable, p = 0.281. The median progression-free survival for these three groups was 7.4, 6.0 and 7.2 months. Multivariate analysis confirmed that trastuzumab treatment was an independent prognostic factor in group A and B patients ( p = 0.017). HER2 positive was an independent adverse prognostic factor in group B and C patients ( p = 0.013). [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
19. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy.
- Author
-
An, Xin, Wang, Fang, Shao, Qiong, Wang, Feng‐Hua, Wang, Zhi‐Qiang, Chen, Cui, Li, Cong, Luo, Hui‐Yan, Zhang, Dong‐Sheng, Xu, Rui‐Hua, and Li, Yu‐Hong
- Subjects
GENE amplification ,STOMACH cancer ,DISEASE prevalence ,CANCER chemotherapy ,METASTASIS ,IMMUNOHISTOCHEMISTRY - Abstract
BACKGROUND Several large studies have reported an extremely low incidence of MET gene amplification (GA) in patients with radically resected gastric cancer. This study was conducted to evaluate the prevalence and prognostic role of MET in patients with recurrent/metastatic gastric cancer who received chemotherapy. METHODS MET GA and protein expression of recurrent/metastatic gastric cancer samples were evaluated by fluorescence in situ hybridization and immunohistochemistry (IHC), respectively. RESULTS This retrospective study included 232 patients with recurrent/metastatic gastric cancer. MET GA and strong protein expression (IHC3+) were observed in 8.3% (19 of 230 samples) and 9.6% (22 of 229 samples) of samples, respectively. A significant correlation was observed between MET GA and protein expression (r = 0.378; P < .001). MET GA was correlated with poor performance status ( P < .001) and poorly differentiated tumors ( P = .0015). Both MET GA and IHC 3+ expression were associated with a substantially shorter median overall survival (OS) and progression-free survival (PFS). The median OS and PFS for patients with MET GA versus those without MET GA were 5.7 months versus 15.5 months ( P < .001) and 3.6 months versus 6.9 months ( P < .001), respectively. The median OS and PFS for patients with MET IHC 3+ expression versus IHC 0 to 2+ expression were 6.3 months versus 15.1 months ( P < .001) and 3.6 months versus 7.0 months ( P < .001), respectively. CONCLUSIONS In patients with recurrent/metastatic gastric cancer, MET amplification and strong protein expression are not rare and appear to be significantly associated with unfavorable clinical outcomes. Cancer 2014;120:675-682. © 2013 American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
20. Prognostic relevance of BRD7 expression in colorectal carcinoma.
- Author
-
Wu, Wen‐Jing, Hu, Kai‐Shun, Chen, Dong‐Liang, Zeng, Zhao‐Lei, Luo, Hui‐Yan, Wang, Feng, Wang, De‐Shen, Wang, Zhi‐Qiang, He, Fan, and Xu, Rui‐Hua
- Subjects
BROMODOMAIN-containing proteins ,NASOPHARYNX cancer ,COLON cancer ,CANCER patients ,IMMUNOHISTOCHEMISTRY ,CELL lines - Abstract
Background BRD7 is a member of bromodomain-containing protein and was found to be a cofactor of P53. Down-regulation of BRD7 has been shown in nasopharyngeal carcinoma cell lines and tissues. However, the clinical role of BRD7 in colorectal cancer remains unknown. Materials and methods Real-time PCR, Western blotting analysis and immunohistochemistry were employed to examine BRD7 expression in CRC cell lines/tissues compared with normal epithelia cells/adjacent non-tumorous tissues. In addition, statistical analyses were applied to evaluate the diagnostic value and associations of BRD7 expression with clinical parameters of patient samples. Results BRD7 was down-regulated in colorectal cancer cell lines and cancerous tissues compared with that in normal colon epithelial cells and adjacent noncancerous tissue samples. BRD7 protein expression was positively correlated with clinical stage ( P < 0·001), T classification ( P = 0·001), N classification ( P < 0·001), M classification ( P < 0·001) and pathologic differentiation ( P = 0·008). Patients with low/none BRD7 expression had shorter overall survival time than those with higher BRD7 expression. Univariate and multivariate analyses indicated BRD7 expression was an independent prognostic factor ( P < 0·001). Conclusion BRD7 may serve as a potential prognostic biomarker of human colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China.
- Author
-
Qiu, Miao-zhen, Cai, Mu-yan, Zhang, Dong-sheng, Wang, Zhi-qiang, Wang, De-shen, Li, Yu-hong, and Xu, Rui-hua
- Subjects
CLINICAL pathology ,PROGNOSIS ,ADENOCARCINOMA ,GASTRECTOMY ,STOMACH cancer treatment ,COMPARATIVE studies - Abstract
Background: According to the Lauren classification, gastric adenocarcinomas are divided into diffuse and intestinal types. The causative attribution explaining the dismal prognosis of diffuse-type remains unknown. Methods: We examined the archive of 1000 patients with gastric adenocarcinomas who received radical gastrectomy in our center and assessed the effect of the Lauren classification on survival in a multivariate approach. Moreover we compared the variation of clinical features between the diffuse-type and intestinal-type and explored the contributing factors for the prognostic difference. Results: There were 805 resectable patients for the final analysis. Diffuse-type comprised of 48.7% in the gastric carcinoma in our group and showed poorer prognosis than intestinal-type (P=0.013). Multivariate analysis revealed that independent prognostic factors for gastric carcinoma patients were T stage (P<0.001), N stage (P<0.001) tumor size (P<0.001) and Lauren classification (P=0.003). For the clinical features, diffuse-type was significantly associated with younger age (p<0.001), female preponderance (p <0.001), distal location (P<0.001), advanced pT (p < 0.001), advanced pN (p < 0.001) and advanced TNM stage (p = 0.027). Conclusions: Diffuse type adenocarcinoma carries a worse prognosis that may be partially explained by the tendency of this subtype to present at more advanced T and N stage. However, Lauren classification has prognostic significance that is independent of T and N stage as well as other prognostic variables based on the multivariate cox analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. The Prognostic Value of Locoregional Interventions for BRAF V600E Metastatic Colorectal Cancer: A Retrospective Cohort Analysis.
- Author
-
Ye, Liu-Fang, Ji, Xiao-Meng, Ren, Chao, Wang, Zhi-Qiang, Lin, Chun-Ping, Chen, Dong-Liang, Cai, Yan-Qing, Jin, Ying, Qiu, Miao-Zhen, Du, Zi-Ming, Xi, Shao-Yan, Zhang, Dong-Sheng, Wang, Feng, Wang, Feng-Hua, Xu, Rui-Hua, Li, Yu-Hong, and Wang, De-Shen
- Subjects
COLORECTAL cancer ,BRAF genes ,PROGRESSION-free survival ,PROGNOSIS ,METASTASIS ,OVERALL survival - Abstract
The prognostic heterogeneity in patients with BRAF V600E metastatic colorectal cancer (mCRC) remains poorly defined. Real-world data of 93 BRAF V600E mCRC patients from Sun Yat-sen University Cancer Center were evaluated using the prognostic factors affecting overall survival (OS). Treatment of metastases served as an independent prognosticator, where curative locoregional interventions (LRIs) were associated with superior clinical outcomes (adjusted hazard ratio (HR): 0.46, 95% confidence interval (CI): 0.22–0.98; p = 0.044). The LRIs group showed an improved median OS of 49.4 months versus 18.3 months for the palliative treatments (PTs) group. The median OS of patients with colorectal liver metastasis (CRLM) was significantly prolonged after undergoing LRIs (42.4 vs. 23.7 months; HR: 0.11, 95% CI: 0.01–1.22; p = 0.030), and patients in the LRIs plus liver-limited or lung-limited metastasis (LLM) group benefited more than those in the LRIs plus non-LLM group when compared to the PTs group (LLM from LRIs vs. PTs, HR: 0.16, 95% CI: 0.04–0.68; p = 0.006. Non-LLM from LRIs vs. PTs, HR: 0.47, 95% CI: 0.21–1.05; p = 0.074). In conclusion, we confirmed the positive prognostic value of LRIs in BRAF V600E mCRC, particularly in patients with CRLM or LLM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.
- Author
-
Lin, Mei, Yang, Qi, You, Rui, Zou, Xiong, Duan, Chong-yang, Liu, You-ping, Huang, Pei-yu, Xie, Yu-long, Wang, Zhi-qiang, Liu, Ting, Chen, Si-Yuan, Hua, Yi-jun, and Chen, Ming-yuan
- Subjects
- *
NASOPHARYNX cancer , *PROGNOSIS , *METASTASIS , *PATIENT selection , *UNIVARIATE analysis - Abstract
Introduction: The current metastatic category (M) of nasopharyngeal carcinoma (NPC) is a "catch-all" category, we previously successfully established a M1 subdivision system based on prognostic metastatic characteristics in epidemic areas. We aimed to figure out metastatic characteristics associated with survival outcomes of NPC in non-epidemic areas.Methods: A total of 428 newly diagnosed de novo metastatic NPC patients from 2010 to 2016 were analyzed from the population-based Surveillance, Epidemiology, and End Results program. Cox proportional hazard ratios (HRs) were used to identify independent prognostic factors for survival.Results: The most frequently involved metastatic locations were the bones (53.04%), the lungs (36.68%), the livers (29.21%) and the distant lymph nodes (24.07%). Univariate analysis indicated that bone involvement (HR = 1.39, 95% CI = 1.09-1.77), liver involvement (HR = 1.44, 95% CI = 1.12-1.85) and multiple metastatic locations (HR = 1.32, 95% CI = 1.04-1.67) were negative prognostic factors of overall survival (OS) for patients with synchronous metastasis. We established a new M1 subdivision system based on metastatic characteristics: M1a, without bone and liver involvement; M1b, single bone or liver involvement; M1c, multiple metastatic locations including bone and/or liver. Multivariate analysis confirmed that our new subcategories were associated with significantly different OS (M1b vs M1a: HR = 1.54, 95% CI = 1.11-2.16; M1c vs M1a: HR = 2.03, 95% CI = 1.47-2.78).Conclusions: Synchronous metastatic NPC patients with multiple metastatic locations involved bone and/or liver were prone to suffer from dismal OS and might need more attentions for selection of treatment modality. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.